Loading
The first adjuvant immunotherapy trial in liver cancer looked positive early, then the benefit vanished with longer follow-up.
IMbrave050, trial NCT04102098 sponsored by Roche and reported in 2023, was the first adjuvant immunotherapy trial in liver cancer, and it looked positive early before the benefit vanished with longer follow-up. It randomised 668 patients to atezolizumab plus bevacizumab or active surveillance after resection or ablation of high-risk hepatocellular carcinoma, and an interim recurrence-free survival benefit prompted enthusiasm, but the updated analysis in 2026 showed the benefit was not sustained and did not support adjuvant use, with only a possible signal in subgroups. OnCo links it to hepatocellular carcinoma, atezolizumab and Ann-Lii Cheng. The record treats it as a lesson about immature interim analyses, and whether any adjuvant strategy can prevent recurrence in liver cancer remains open.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
668 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Recurrence-free survival (interim)primary | Atezolizumab + bevacizumab | 334 | - | 0.72 (0.56 to 0.93) | - | link |
| Surveillance | 334 | - |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Atezolizumab, Roche / Genentech, Immune checkpoint inhibitors and the tag failure.
Shares Hepatocellular carcinoma and the tag failure.
Shares Roche / Genentech and the tag failure.
Shares Atezolizumab, Roche / Genentech, Immune checkpoint inhibitors and the tag failure.
Shares Hepatocellular carcinoma and the tag failure.
Shares Roche / Genentech and the tag failure.
Shares Immune checkpoint inhibitors and the tag failure.
Shares Immune checkpoint inhibitors and the tag failure.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/